Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model

Abstract Background aims Mesenchymal stromal cells (MSC) have been shown to be a promising candidate for tissue regeneration and cancer therapy. However, their therapeutic potential against chemotherapy-induced side-effects remains unclear. Methods We treated murine Lewis lung carcinoma (LLC) and xe...

Full description

Saved in:
Bibliographic Details
Published in:Cytotherapy (Oxford, England) England), 2012-04, Vol.14 (4), p.412-422
Main Authors: Di, Guo-Hu, Jiang, Shu, Li, Fu-Quan, Sun, Jun-Zhong, Wu, Chu-Tse, Hu, Xiang, Duan, Hai-Feng
Format: Article
Language:English
Subjects:
Advanced Basic Science
Animals
Antibiotics, Antineoplastic - therapeutic use
Carcinoma, Lewis Lung - drug therapy
Carcinoma, Lewis Lung - therapy
chemotherapy
Colonic Neoplasms - drug therapy
Colonic Neoplasms - therapy
Doxorubicin - therapeutic use
Humans
Mesenchymal Stromal Cells - cytology
Mesenchymal Stromal Cells - metabolism
metastasis
Mice
Other
side-effects
Umbilical Cord - cytology
umbilical cord-derived mesenchymal stromal cells
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background aims Mesenchymal stromal cells (MSC) have been shown to be a promising candidate for tissue regeneration and cancer therapy. However, their therapeutic potential against chemotherapy-induced side-effects remains unclear. Methods We treated murine Lewis lung carcinoma (LLC) and xenograft human colon tumors with adriamycin (ADM) for 3 consecutive days followed by one intravenous (i.v.) injection of human umbilical cord (hUC) MSC for several cycles. Results MSC treatment mitigated ADM-induced cardiomyopathy, reduced the extent of ADM-induced apoptosis in intestinal crypts, suppressed body weight loss in mice treated with ADM and increased the survival rate of mice treated with a lethal dose of ADM. The examination of hematologic parameters indicated a moderate recovery in MSC-injected mice. Systemic administration of MSC did not increase the growth of murine LLC cells and human colon carcinoma in vivo while it strongly inhibited the lung metastases of LLC cells. Conclusions We evaluated the prophylactic and therapeutic action of hUC MSC on the chemotherapy agent ADM-induced side-effects in two different tumor models. Our observations suggest that MSC can be used as auxiliary means in chemotherapy for certain tumor types.
ISSN:1465-3249
1477-2566
DOI:10.3109/14653249.2011.646044